Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

OBJECTIVES: To characterise the safety and tolerability of nintedanib and the dose adjustments used to manage adverse events in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). METHODS: In the SENSCIS trial, patients with SSc-ILD were randomised to receive nintedanib...

Descripción completa

Detalles Bibliográficos
Autores principales: Seibold, James R, Maher, Toby M, Highland, Kristin B, Assassi, Shervin, Azuma, Arata, Hummers, Laura Kathleen, Costabel, Ulrich, von Wangenheim, Ute, Kohlbrenner, Veronika, Gahlemann, Martina, Alves, Margarida, Distler, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569371/
https://www.ncbi.nlm.nih.gov/pubmed/32759258
http://dx.doi.org/10.1136/annrheumdis-2020-217331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569371/
https://www.ncbi.nlm.nih.gov/pubmed/32759258
http://dx.doi.org/10.1136/annrheumdis-2020-217331

Ejemplares similares